+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

Journal of Clinical Oncology 15(2): 610-619

Purpose: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. Subjects and Methods: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). Results: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio (HRa) = 2.0; 95% confidence interval (CI), 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. Conclusion: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 008789755

Download citation: RISBibTeXText

PMID: 9053484

DOI: 10.1200/jco.1997.15.2.610

Related references

The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes. Jundishapur Journal of Microbiology 9(4): E32728, 2016

Predictors of seropositivity to human papillomavirus type 53: one of the most prevalent high risk-related cervical human papillomaviruses. Viral Immunology 21(3): 371-377, 2008

Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. Journal of Infectious Diseases 170(6): 1424-1431, 1994

Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma. Open Virology Journal 2: 74-81, 2008

Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. American Journal of Epidemiology 153(8): 732-739, 2001

Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. American Journal of Epidemiology 153(8): 723-731, 2001

Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients. Fems Immunology and Medical Microbiology 54(2): 167-176, 2008

Co-carcinogenesis: Human Papillomaviruses, Coal Tar Derivatives, and Squamous Cell Cervical Cancer. Frontiers in Microbiology 8: 2253, 2017

Human papillomavirus 16-positive uterine cervical squamous cell carcinoma with coinfection with human papillomavirus 34 has a lower incidence in lymph node metastasis than that without coinfection with human papillomavirus 34. Pathobiology 80(5): 259-264, 2013

Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer 74(8): 2307-2313, 1994

Implications of human papillomavirus type for survival in cervical squamous cell carcinoma. International Journal of Gynecological Cancer 5(5): 341-345, 1995

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clinical Cancer Research 14(1): 178-187, 2008

Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. Journal of Virology 81(6): 2869-2879, 2007

Human papillomavirus hpv infections and cervical squamous cell cancer. European Journal of Cancer and Clinical Oncology 23(11): 1802-1803, 1987

Human papillomavirus and tar hypothesis for squamous cell cervical cancer. Journal of Biosciences 35(3): 331-337, 2010